Supernus Pharmaceuticals, Inc. · NASDAQ:SUPN

Supernus Pharmaceuticals — Technical Presentation (December 2020)

8 slides from Supernus Pharmaceuticals's technical presentation, Dec 23, 2020

  1. Slide 1: SPN-812 Topline Results – ADHD Phase III Study in Adults (P306)

    © 2020 Supernus Pharmaceuticals, Inc. All Rights Reserved. 1 Supernus Pharmaceuticals SPN-812 Topline Results – ADHD Phase III Study in Adults (P306) December 2020 Exhibit 99.2

  2. Slide 2: Safe Harbor Statement

    © 2020 Supernus Pharmaceuticals, Inc. All Rights Reserved. Safe Harbor Statement This presentation and other matters discussed today or answers that may be given to questions asked include forward-looking statements within the meaning of the federal securities laws. These statements, among other thi

  3. Slide 3: SPN-812 Phase III Adult Study P306

    © 2020 Supernus Pharmaceuticals, Inc. All Rights Reserved. SPN-812 Phase III Adult Study P306 N = 374 Study Design ADHD Patients Adults Randomized, double-blind, two arm placebo-controlled study Starting dose of 200mg on week 1, 400mg on week 2, followed by flexible dosing between 200mg and 600mg pe

  4. Slide 4: SPN-812 Phase III Adult Study: Fast Onset of Action – Primary Endpoint

    © 2020 Supernus Pharmaceuticals, Inc. All Rights Reserved. SPN-812 Phase III Adult Study: Fast Onset of Action Efficacy Starting as Early as Week 2 – Primary Endpoint Primary Endpoint Visit Statistics Placebo (N=179) 200mg to 600mg1 (N=175) Baseline Mean 37.6 38.5 Week 1 p-value 0.2941 Week 2 p-valu

  5. Slide 5: SPN-812 Phase III Adult Study: Fast Onset of Action – Secondary Endpoint

    © 2020 Supernus Pharmaceuticals, Inc. All Rights Reserved. SPN-812 Phase III Adult Study: Fast Onset of Action Efficacy Starting as Early as Week 2 – Secondary Endpoint Clinical Global Impression - Severity Score (CGI-S) Visit Statistics Placebo (N=179) 200mg to 600mg1 (N=175) Baseline Mean 4.6 4.6

  6. Slide 6: Significant Reduction in Inattention Subscale

    © 2020 Supernus Pharmaceuticals, Inc. All Rights Reserved. SPN-812 Phase III Adult Study Significant Reduction in Inattention Subscale Inattention Subscale Visit Statistics Placebo (N=179) 200mg to 600mg1 (N=175) Baseline Mean 21.1 21.5 Week 1 p-value 0.1127 Week 2 p-value 0.0113 Week 3 p-value 0.00

  7. Slide 7: Significant Reduction in Hyperactivity/Impulsivity Subscale

    © 2020 Supernus Pharmaceuticals, Inc. All Rights Reserved. SPN-812 Phase III Adult Study Significant Reduction in Hyperactivity/Impulsivity Subscale Hyperactivity/Impulsivity Subscale Visit Statistics Placebo (N=179) 200mg to 600mg1 (N=175) Baseline Mean 16.5 17.0 Week 1 p-value 0.9991 Week 2 p-valu

  8. Slide 8: Summary of Treatment Related Adverse Events (Safety Population)

    © 2020 Supernus Pharmaceuticals, Inc. All Rights Reserved. 8 AEs = Adverse Events SPN-812 Phase III Adult Study Summary of Treatment Related Adverse Events (Safety Population) Number (%) of Patients - Treatment Related AEs with ≥ 5% Incidence P306 Placebo (N=183) SPN-812 (N=189) Insomnia 9 (4.9) 43

Supernus Pharmaceuticals — Technical Presentation (December 2020) on 6ix